About this trial
The primary objective of the study is to determine a change in the gut microbiome (GM) measured before and after neo-adjuvant chemotherapy or chemoradiation for early-stage locally advanced Breast or GI cancers and to examine the association of this change in the GM with pathological response at the time of surgery.
Blood and stool samples will be collected before commencing neo-adjuvant treatment, after completion of neo-adjuvant treatment and in 6 six months after completion of neoadjuvant treatment.
Patient Profile
Patients with Breast Cancer – all subtypes (HER-2 positive, ER and PR positive and TNBC) treated with neoadjuvant treatment including monoclonal antibodies.
Patients with Rectal Cancer treated with neoadjuvant therapy.
Patients Oesophageal Cancer treated with a neoadjuvant approach including gastro-oesophageal junctional carcinoma.
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Gut Microbiome |
|---|---|
| Number: | 24-25 |
| Full Title: | A prospective observational study investigating the impact of the gut microbiome constitution on the response to neo-adjuvant chemotherapy and neo-adjuvant chemo-radiation in early-stage breast |
| Principal Investigator: | Professor Bryan Hennessy |
|---|---|
| Type: | Collaborative |
| Sponsor: | Beaumont Hospital |
| Recruitment Started: |
Global: n/a Ireland: April 2023 |
| Global Recruitment Target: | n/a |
|---|---|
| Ireland Recruitment Target: | 120 |